DGAP-Adhoc Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial (INTR@PID Lung 037)

Nachrichtenquelle: EQS Group AG
20.01.2021, 13:30  |  138   |   |   

DGAP-Ad-hoc: Merck KGaA / Key word(s): Study/Study results
Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial (INTR@PID Lung 037)

20-Jan-2021 / 13:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Merck KGaA (the "Company") is investigating a bifunctional immunotherapy, bintrafusp alfa (anti-PD-L1/TGF-beta trap), as a potential therapy for difficult to treat cancers.

While reviewing the totality of data from the ongoing clinical trial INTR@PID Lung 037 in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC) that have high expression of PD-L1 (the "Clinical Trial"), the Independent Data Monitoring Committee recommended on January 19, 2021 to discontinue the Clinical Trial. Based on this recommendation, the Company has made the decision to discontinue the Clinical Trial, as the
study is unlikely to meet the primary efficacy endpoint. The recommendation by the Independent Data Monitoring Committee and the Company's decision is related only to this Clinical Trial.

Bintrafusp alfa is currently under clinical investigation and not approved for any use anywhere in the world.

An investor and analyst call with the Company's management is scheduled for 2:00 pm (CET).



Andreas Cezanne - Head of Corporate Media Relations
Merck KGaA
Frankfurter Straße 250
64293 Darmstadt
Germany
Phone: +49 151-14542702

20-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Handeln Sie Ihre Einschätzung zu Merck KGaA!
Short
Basispreis 145,56€
Hebel 14,90
Ask 1,15
Long
Basispreis 127,46€
Hebel 13,72
Ask 0,83

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.


Language: English
Company: Merck KGaA
Frankfurter Str. 250
64293 Darmstadt
Germany
Phone: +49 (0)6151 72 - 6328
E-mail: Friederike.Segeberg@merckgroup.com
Internet: https://www.merckgroup.com/de
ISIN: DE0006599905
WKN: 659990
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX
EQS News ID: 1161977

 
End of Announcement DGAP News Service

1161977  20-Jan-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1161977&application_name=news&site_id=wallstreet

Diesen Artikel teilen

Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

DGAP-Adhoc Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial (INTR@PID Lung 037) DGAP-Ad-hoc: Merck KGaA / Key word(s): Study/Study results Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial (INTR@PID Lung 037) 20-Jan-2021 / 13:30 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel